MENU

CMMB Stock Chemomab Therapeutics (CMMB, $1.18) Stochastic Oscillator left the oversold zone on April 14, 2025

A.I.dvisor
at Tickeron.com
Loading...
CMMB - Chemomab Therapeutics Ltd
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $1.1805
Daily change: +$0.1138 (+10.67%)
Daily volume: 79.3K
Capitalization: $22.3M
Industry: Biotechnology
This is a signal that CMMB's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 66 similar cases where CMMB's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

CMMB in upward trend: price expected to rise as it breaks its lower Bollinger Band on March 25, 2025

CMMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where CMMB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CMMB's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 14, 2025. You may want to consider a long position or call options on CMMB as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CMMB just turned positive on April 11, 2025. Looking at past instances where CMMB's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 50-day moving average for CMMB moved below the 200-day moving average on April 09, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CMMB entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.560) is normal, around the industry mean (13.444). P/E Ratio (0.000) is within average values for comparable stocks, (62.833). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.754). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (250.783).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CMMB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of biopharmaceutical services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Kiryat Atidim
Phone
+972 773310156
Employees
20
Web
https://www.chemomab.com